Germany's employers lost an estimated €82 billion to sick leave costs in 2024 alone. That is because the average employee called in sick for 19.4 days, the highest figure in Europe and nearly double the rate recorded fifteen years ago. In boardrooms and HR departments across the country, betriebliches Gesundheitsmanagement, BGM, has become the standard response. Yoga on Thursdays. Ergonomic assessments. Lunch seminars about sleep hygiene. Subsidised fruit baskets.
And yet the numbers keep rising.
This isn't a criticism of BGM. Workplace health management is a genuinely valuable discipline, and the evidence for well-designed programmes is solid. The problem is what most BGM Konzepte don't include: any systematic look at what is actually happening inside your employees' bodies. Stress awareness workshops can't fix vitamin D deficiency. Standing desks don't resolve insulin resistance. And no amount of mindfulness training compensates for ferritin levels so low that a person's brain is running on fumes.
The missing layer isn't more programmes. It's data.
Here is why BGM alone isn't solving it. The scale of Germany's Fehlzeitenquote is extraordinary even by European standards. The Techniker Krankenkasse reported 19.4 average sick days per employee in 2023, compared to roughly 11 days in Denmark and 9 in Switzerland. The Institut der deutschen Wirtschaft estimates the resulting employer costs at over €82 billion annually once you factor in continued salary payments, replacement costs, and productivity losses. [[1]] [[2]] [[3]]
The three dominant causes have remained stubbornly consistent for years: respiratory infections, mental health disorders (depression, burnout, anxiety), and musculoskeletal complaints. Together, these account for roughly 60% of all sick days across most industry sectors.
What's striking is that two of these three categories: mental health disorders and musculoskeletal complaints, are directly connected to underlying biological states that are entirely testable. Elevated cortisol, depleted ferritin, low vitamin D, disturbed thyroid function, and chronic low-grade inflammation all manifest as the precise symptoms that eventually become sick days: persistent fatigue, difficulty concentrating, low mood, muscle pain, recurring infections, and burnout.
Most employees don't reach HR with a note saying "I have undetected hypothyroidism." They arrive with fatigue, reduced performance, and eventually a Krankschreibung. Standard BGM programmes meet them there, at the symptom level, when the more useful intervention was possible months earlier.
If you're investing in BGM, the question worth asking is: what biological data are you working from?
A well-designed BGM Konzept typically covers four domains: workplace ergonomics (Verhältnisprävention), behavioural health promotion (Verhaltensprävention), occupational health services (Arbeitsmedizin), and employee assistance programmes. These are legitimate, evidence-based interventions with demonstrated value.
But look at what each of them assumes: that the employee is essentially biologically healthy and needs support to maintain healthy habits. The ergonomic workstation helps someone whose back pain is posture-related. The stress management course helps someone whose cortisol rhythm is fundamentally intact. The nutrition coaching is useful for someone whose fatigue comes from dietary habits rather than iron deficiency or subclinical hypothyroidism.
What happens when the underlying biology is compromised? When someone's ferritin has fallen below 25 µg/L, technically "within normal range" by most lab references but firmly associated with cognitive impairment, chronic fatigue, and reduced exercise tolerance? A mindfulness app doesn't move ferritin. Neither does a standing desk.
This is the structural gap in most BGM programmes: they address behaviour without first addressing biology. They presume that if you give employees better tools and information, their bodies will respond. Sometimes that's true. Often it isn't, because the reason performance is declining isn't a knowledge gap, it's a biomarker deficit.
The Arbeitsmediziner (occupational physician) is theoretically positioned to bridge this gap, but in practice is constrained to investigating occupational exposures and legal compliance thresholds. A routine Vorsorgeuntersuchung does not include ferritin, free testosterone, fasting insulin, or hs-CRP. It isn't designed to.
Aniva's 140+ biomarker panel covers exactly the markers missing from standard BGM and occupational screening — metabolic health, inflammation, iron, thyroid, hormones, and vitamins. See the full biomarker list →
Absenteeism, days when employees don't show up, is easily quantified. It appears in HR data, costs something definite, and motivates action. Präsentismus, days when employees show up but function significantly below capacity, is far more expensive and almost completely invisible.
Research from the Institut für Betriebliche Gesundheitsförderung (iga) suggests that presenteeism costs approximately twice what absenteeism costs. A Booz & Company study found that in Switzerland, presenteeism accounted for approximately two-thirds of total health-related productivity losses. UK estimates put the annual national cost at over £21 billion: more than double the cost of sick days. [[4]] [[5]]
The drivers of presenteeism are precisely the conditions that blood testing catches and conventional BGM doesn't: subclinical thyroid dysfunction, iron deficiency without anaemia, early insulin resistance, vitamin D deficiency, and elevated hs-CRP: the inflammation marker linked to both reduced cognitive performance and depression.
An employee with ferritin at 18 µg/L, vitamin D at 28 nmol/L, and a mildly elevated hs-CRP is showing up to work every day. HR data shows zero sick days. But their concentration is impaired, their reaction time is slower, their mood is lower, and their susceptibility to the next respiratory infection is higher. They are present and performing at perhaps 70% of their capacity. Nobody, including the employee, has any way of knowing this from standard occupational health screening.
This is the presenteeism problem that biomarker testing addresses directly.
The German healthcare system, despite its considerable strengths, has a structural blind spot for the population we describe as the "pre-patient": someone who isn't sick enough to receive diagnostic attention but whose biology is deteriorating in ways that will eventually produce sick days, burnout, or chronic disease.
The statutory Check-up 35 tests five blood values every three years. The groĂźes Blutbild, despite its comprehensive-sounding name, examines blood cell counts but tests nothing about metabolic health, thyroid function, inflammation, iron stores, or hormones. We explored this structural gap in our guide to the groĂźes Blutbild.
The result is that most employees in Germany have never had their ferritin tested. Most have never had their fasting insulin checked. Most have no idea whether their vitamin D is in the range associated with optimal immune function or whether it has spent the last three winters significantly below it.
Consider what this means in practice. Germany's northern latitude makes meaningful vitamin D synthesis from sunlight essentially impossible between October and March. The Robert Koch Institut's DEGS study found that approximately 56% of German adults have vitamin D levels below 50 nmol/L: a level associated in the research literature with impaired immune function, fatigue, and mood disorders. [[6]] An employee working 45 weeks of the year in a northern German city, mostly indoors, is highly likely to be in this group for most of the working year.
This isn't a lifestyle problem. It can't be addressed with better stress management coaching. It requires a test — and then, if indicated, a supplement at an appropriate dose for that individual's actual level. Our article on vitamin D in Northern Europe covers the evidence in detail.
The same logic applies to iron. Among women of reproductive age, iron deficiency without clinical anaemia affects an estimated 15–30% across Europe. It is the most common nutritional deficiency on the continent, produces the exact symptoms that HR associates with stress and burnout: fatigue, difficulty concentrating, low motivation, and is reliably invisible to standard occupational health screening. A 2012 French RCT published in the Canadian Medical Association Journal found that iron supplementation reduced fatigue by nearly 50% in non-anaemic women with ferritin below 50 µg/L. [[7]] The intervention was a blood test and a supplement. The BGM equivalent — better work-life balance coaching — wouldn't have touched it.
A comprehensive biomarker panel doesn't replace the other components of BGM. Ergonomics, behavioural health promotion, and occupational medicine all remain essential. What it adds is a biological baseline, a data layer that tells you which employees are working below capacity due to correctable medical factors, and which are genuinely well.
The markers that matter most in a workplace health context are not exotic or expensive. They're the ones missing from the standard occupational screening panel.
Iron deficiency (Ferritin). The most under-diagnosed cause of workplace fatigue, particularly in women. Standard occupational screening tests haemoglobin — which only drops once iron deficiency becomes severe. Ferritin, the direct measure of iron stores, is almost never included. An employee with ferritin at 15 µg/L has months of declining performance, concentration difficulty, and increased sick day risk ahead of them. A test, followed by supplementation if indicated, resolves this. [[7]] [[11]]
Vitamin D deficiency. Directly associated with immune function, mood regulation, and musculoskeletal health — the three leading causes of sick days in Germany. Deficiency is endemic during winter months and cannot be adequately addressed without knowing the individual's baseline level. Supplementing without testing means dosing blind: some employees need 1,000 IU, others 5,000 IU, and a few are already above optimal range and should not supplement at all. [[6]]
Thyroid dysfunction. An estimated 4–5% of Europeans have undiagnosed subclinical hypothyroidism. [[8]] Symptoms include fatigue, weight gain, cold sensitivity, and brain fog — a constellation that looks identical to burnout in an HR context. A full thyroid panel including TSH, free T3, free T4, and antibodies can reveal the biological explanation for performance decline that months of coaching will never address.
Chronic low-grade inflammation (hs-CRP). High-sensitivity C-reactive protein is the most clinically validated marker of systemic inflammatory load. Elevated hs-CRP is independently associated with cardiovascular risk, impaired cognitive function, and depression. [[9]] It responds to modifiable lifestyle factors — sleep quality, dietary patterns, exercise consistency — but you cannot track or incentivise the response without measuring the baseline.
Insulin resistance and metabolic dysfunction. Fasting insulin — almost never included in occupational health screening — is the earliest detectable marker of the metabolic dysfunction that eventually becomes type 2 diabetes, cardiovascular disease, and obesity. Elevated fasting insulin is present in an estimated 20–30% of apparently healthy adults. It drives weight gain, afternoon energy crashes, brain fog, and sugar cravings: the exact complaints HR hears as "stress symptoms." Catching it at Stage 1, when it is fully reversible through lifestyle intervention, requires one blood test. Our article on blood sugar and metabolic health explains the mechanism in full.
Aniva tests all five of these markers as standard . Alongside up to 500+ others depending on add-on tests at an ISO 15189-certified German laboratory, starting from for €199 per person per year. Create a free account and we will reach out to discuss creating a free trial corporate account.
Germany's tax framework includes a provision that most employers dramatically underutilise: §3 Nr. 34 EStG allows employers to provide up to €600 per employee per year in certified health promotion measures, completely free of income tax and social security contributions. [[10]]
This is a Freibetrag, an allowance, not a Freigrenze (threshold). The practical difference matters: if you invest €800 per employee, the first €600 is tax-free and only the remaining €200 is treated as a taxable benefit. A Freigrenze would make the entire amount taxable upon exceeding the limit.
To qualify under §3 Nr. 34 EStG, measures must meet two criteria. First, they must be provided additionally to regular salary, salary conversion or offset against existing benefits does not qualify. Second, they must meet the quality and certification standards of §§20 and 20b SGB V, meaning they must align with the GKV-Spitzenverband's prevention guidelines.
For a company with 100 employees investing €600 per person in qualifying health promotion, the employer saves approximately €25,000–€35,000 in social security contributions (employer's share), in addition to employees receiving the full benefit tax-free. The BGM investment becomes significantly cheaper than its headline cost. Consult a qualified Steuerberater regarding the qualification of specific health testing services under §3 Nr. 34 EStG for your circumstances.
Adding a structured biomarker testing component creates a data foundation that makes everything else in your BGM programme more effective. Here's what that looks like in practice.
Step 1: Biological baseline. Employees receive a comprehensive blood panel covering metabolic health, inflammatory markers, iron status, thyroid function, hormones, and key vitamins. Results are individual and confidential:Â HR sees aggregated anonymised data, not individual results.
Step 2: Targeted intervention. Where testing reveals correctable deficiencies, and experience suggests they are present in the majority of employees who have never had comprehensive testing, intervention is specific and proportionate. Vitamin D supplementation at the appropriate dose. Iron supplementation where ferritin is low. GP referral where thyroid function warrants attention.
Step 3: Follow-up measurement. A follow-up panel 6–12 months later measures what actually changed. This transforms BGM from an output measure (we ran ten wellbeing workshops) to an outcome measure (the percentage of employees with vitamin D in the optimal range increased from 32% to 71%). The difference is material: one answers "did we do something?" and the other answers "did anything improve?"
Step 4: Programme adjustment. Aggregated anonymised data shapes future BGM investment. If 40% of your workforce has elevated hs-CRP, that's a signal about sleep quality, dietary patterns, or chronic stress that informs targeted programming. The biomarker data makes the rest of the BGM strategy evidence-based rather than presumptive.
This is the fundamental shift: from BGM as a welfare offering to BGM as a data-driven health strategy. Speak to Aniva's corporate team about integrating biomarker testing into your BGM Konzept →
Germany's sick leave rates are rising despite significant BGM investment. The gap isn't in the quality of the programmes. It's in the absence of biological data to identify which employees are genuinely healthy, which are functioning below capacity due to correctable deficiencies, and whether any of this is improving over time.
Betriebliches Gesundheitsmanagement works best when it works from evidence. The most important evidence is what's happening inside your employees' bodies, not as a surveillance exercise, but as a genuinely useful health benefit that most employees have never been offered.
If you're designing or reviewing a BGM Konzept and want to understand what adding a comprehensive biomarker layer looks like in practice, contact Aniva's corporate team →. Or explore Aniva's full biomarker panel →
This article is for informational purposes only and does not constitute medical, legal, or tax advice. Employers considering workplace health testing programmes should consult with qualified Arbeitsmediziner, HR legal advisers, and tax professionals regarding their specific circumstances. Always ensure employee health data is handled in accordance with DSGVO and applicable employment law.
